Literature DB >> 11461078

Mutation analysis of the CHK2 gene in families with hereditary breast cancer.

M Allinen1, P Huusko, S Mäntyniemi, V Launonen, R Winqvist.   

Abstract

Recently CHK2 was functionally linked to the p53 pathway, and mutations in these two genes seem to result in a similar Li-Fraumeni syndrome (LFS) or Li-Fraumeni-like syndrome (LFL) multi-cancer phenotype frequently including breast cancer. As CHK2 has been found to bind and regulate BRCA1, the product of one of the 2 known major susceptibility genes to hereditary breast cancer, it also more directly makes CHK2 a suitable candidate gene for hereditary predisposition to breast cancer. Here we have screened 79 Finnish hereditary breast cancer families for germline CHK2 alterations. Twenty-one of these families also fulfilled the criteria for LFL or LFS. All families had previously been found negative for germline BRCA1, BRCA2 and TP53 mutations, together explaining about 23% of hereditary predisposition to breast cancer in our country. Only one missense-type mutation, Ile(157)-->Thr(157), was detected. The high Ile(157)--> Thr(157)mutation frequency (6.5%) observed in healthy controls and the lack of other mutations suggest that CHK2 does not contribute significantly to the hereditary breast cancer or LFL-associated breast cancer risk, at least not in the Finnish population. For Ile(157)--> Thr(157)our result deviates from what has been reported previously.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11461078      PMCID: PMC2364033          DOI: 10.1054/bjoc.2001.1858

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  20 in total

1.  Conformation sensitive gel electrophoresis for simple and accurate detection of mutations: comparison with denaturing gradient gel electrophoresis and nucleotide sequencing.

Authors:  J Körkkö; S Annunen; T Pihlajamaa; D J Prockop; L Ala-Kokko
Journal:  Proc Natl Acad Sci U S A       Date:  1998-02-17       Impact factor: 11.205

2.  Evidence of founder mutations in Finnish BRCA1 and BRCA2 families.

Authors:  P Huusko; K Pääkkönen; V Launonen; M Pöyhönen; G Blanco; A Kauppila; U Puistola; H Kiviniemi; M Kujala; J Leisti; R Winqvist
Journal:  Am J Hum Genet       Date:  1998-06       Impact factor: 11.025

3.  A low proportion of BRCA2 mutations in Finnish breast cancer families.

Authors:  P Vehmanen; L S Friedman; H Eerola; L Sarantaus; S Pyrhönen; B A Ponder; T Muhonen; H Nevanlinna
Journal:  Am J Hum Genet       Date:  1997-05       Impact factor: 11.025

4.  Third international workshop on collaborative interdisciplinary studies of p53 and other predisposing genes in Li-Fraumeni syndrome.

Authors:  C Eng; K Schneider; J F Fraumeni; F P Li
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  1997-05       Impact factor: 4.254

5.  Heterozygous germ line hCHK2 mutations in Li-Fraumeni syndrome.

Authors:  D W Bell; J M Varley; T E Szydlo; D H Kang; D C Wahrer; K E Shannon; M Lubratovich; S J Verselis; K J Isselbacher; J F Fraumeni; J M Birch; F P Li; J E Garber; D A Haber
Journal:  Science       Date:  1999-12-24       Impact factor: 47.728

6.  Identification of the breast cancer susceptibility gene BRCA2.

Authors:  R Wooster; G Bignell; J Lancaster; S Swift; S Seal; J Mangion; N Collins; S Gregory; C Gumbs; G Micklem
Journal:  Nature       Date:  1995 Dec 21-28       Impact factor: 49.962

7.  A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1.

Authors:  Y Miki; J Swensen; D Shattuck-Eidens; P A Futreal; K Harshman; S Tavtigian; Q Liu; C Cochran; L M Bennett; W Ding
Journal:  Science       Date:  1994-10-07       Impact factor: 47.728

8.  Follow-up study of twenty-four families with Li-Fraumeni syndrome.

Authors:  J E Garber; A M Goldstein; A F Kantor; M G Dreyfus; J F Fraumeni; F P Li
Journal:  Cancer Res       Date:  1991-11-15       Impact factor: 12.701

9.  Low proportion of BRCA1 and BRCA2 mutations in Finnish breast cancer families: evidence for additional susceptibility genes.

Authors:  P Vehmanen; L S Friedman; H Eerola; M McClure; B Ward; L Sarantaus; T Kainu; K Syrjäkoski; S Pyrhönen; O P Kallioniemi; T Muhonen; M Luce; T S Frank; H Nevanlinna
Journal:  Hum Mol Genet       Date:  1997-12       Impact factor: 6.150

10.  How many more breast cancer predisposition genes are there?

Authors:  D F Easton
Journal:  Breast Cancer Res       Date:  1999-08-23       Impact factor: 6.466

View more
  27 in total

1.  CHEK2 mutations in primary glioblastomas.

Authors:  Satu-Leena Sallinen; Tarja Ikonen; Hannu Haapasalo; Johanna Schleutker
Journal:  J Neurooncol       Date:  2005-08       Impact factor: 4.130

Review 2.  Hereditary breast cancer and the BRCA1-associated FANCJ/BACH1/BRIP1.

Authors:  Sharon B Cantor; Shawna Guillemette
Journal:  Future Oncol       Date:  2011-02       Impact factor: 3.404

3.  Irrelevance of CHEK2 variants to diagnosis of breast/ovarian cancer predisposition in Polish cohort.

Authors:  Aleksander Myszka; Pawel Karpinski; Ryszard Slezak; Halina Czemarmazowicz; Agnieszka Stembalska; Justyna Gil; Izabela Laczmanska; Damian Bednarczyk; Elzbieta Szmida; Maria Malgorzata Sasiadek
Journal:  J Appl Genet       Date:  2010-12-01       Impact factor: 3.240

4.  Uterus hyperplasia and increased carcinogen-induced tumorigenesis in mice carrying a targeted mutation of the Chk2 phosphorylation site in Brca1.

Authors:  Sang Soo Kim; Liu Cao; Cuiling Li; Xiaoling Xu; L Julie Huber; Lewis A Chodosh; Chu-Xia Deng
Journal:  Mol Cell Biol       Date:  2004-11       Impact factor: 4.272

5.  Mutations in CHEK2 associated with prostate cancer risk.

Authors:  Xiangyang Dong; Liang Wang; Ken Taniguchi; Xianshu Wang; Julie M Cunningham; Shannon K McDonnell; Chiping Qian; Angela F Marks; Susan L Slager; Brett J Peterson; David I Smith; John C Cheville; Michael L Blute; Steve J Jacobsen; Daniel J Schaid; Donald J Tindall; Stephen N Thibodeau; Wanguo Liu
Journal:  Am J Hum Genet       Date:  2003-01-17       Impact factor: 11.025

6.  Haplotypes of the I157T CHEK2 germline mutation in ethnically diverse populations.

Authors:  Bella Kaufman; Yael Laitman; Jacek Gronwald; Robert Winqvist; Arvids Irmejs; Jan Lubinski; Katri Pylkäs; Janis Gardovskis; Edvins Miklasevics; Eitan Friedman
Journal:  Fam Cancer       Date:  2009-07-17       Impact factor: 2.375

7.  Mutation analysis of the AATF gene in breast cancer families.

Authors:  Maria Haanpää; Mervi Reiman; Jenni Nikkilä; Hannele Erkko; Katri Pylkäs; Robert Winqvist
Journal:  BMC Cancer       Date:  2009-12-21       Impact factor: 4.430

Review 8.  Genetic counseling and testing for common hereditary breast cancer syndromes: a paper from the 2007 William Beaumont hospital symposium on molecular pathology.

Authors:  Dawn C Allain
Journal:  J Mol Diagn       Date:  2008-08-07       Impact factor: 5.568

9.  Genetic and functional analysis of CHEK2 (CHK2) variants in multiethnic cohorts.

Authors:  Daphne W Bell; Sang H Kim; Andrew K Godwin; Taryn A Schiripo; Patricia L Harris; Sara M Haserlat; Doke C R Wahrer; Christopher A Haiman; Mary B Daly; Kristin B Niendorf; Matthew R Smith; Dennis C Sgroi; Judy E Garber; Olufunmilayo I Olopade; Loic Le Marchand; Brian E Henderson; David Altshuler; Daniel A Haber; Matthew L Freedman
Journal:  Int J Cancer       Date:  2007-12-15       Impact factor: 7.396

10.  The contribution of CHEK2 to the TP53-negative Li-Fraumeni phenotype.

Authors:  Marielle W G Ruijs; Annegien Broeks; Fred H Menko; Margreet G E M Ausems; Anja Wagner; Rogier Oldenburg; Hanne Meijers-Heijboer; Laura J van't Veer; Senno Verhoef
Journal:  Hered Cancer Clin Pract       Date:  2009-02-17       Impact factor: 2.857

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.